Cardiac hypertrophy in mice expressing unphosphorylatable phospholemman

Andrii Boguslavskyi, Davor Pavlovic, Karen Aughton, James E. Clark, Jacqueline Howie, William Fuller, Michael J. Shattock (Lead / Corresponding author)

    Research output: Contribution to journalArticle

    19 Citations (Scopus)

    Abstract

    Aims Elevation of intracellular Na in the failing myocardium contributes to contractile dysfunction, the negative force–frequency relationship, and arrhythmias. Although phospholemman (PLM) is recognized to form the link between signalling pathways and Na/K pump activity, the possibility that defects in its regulation contribute to elevation of intracellular Na has not been investigated. Our aim was to test the hypothesis that the prevention of PLM phosphorylation in a PLM3SA knock-in mouse (in which PLM has been rendered unphosphorylatable) will exacerbate cardiac hypertrophy and cellular Na overload. Testing this hypothesis should determine whether changes in PLM phosphorylation are simply bystander effects or are causally involved in disease progression. Methods and results In wild-type (WT) mice, aortic constriction resulted in hypophosphorylation of PLM with no change in Na/K pump expression. This under-phosphorylation of PLM occurred at 3 days post-banding and was associated with a progressive decline in Na/K pump current and elevation of [Na]i. Echocardiography, morphometry, and pressure-volume (PV) catheterization confirmed remodelling, dilation, and contractile dysfunction, respectively. In PLM3SA mice, expression of Na/K ATPase was increased and PLM decreased such that net Na/K pump current under quiescent conditions was unchanged (cf. WT myocytes); [Na+]i was increased and forward-mode Na/Ca exchanger was reduced in paced PLM3SA myocytes. Cardiac hypertrophy and Na/K pump inhibition were significantly exacerbated in banded PLM3SA mice compared with banded WT. Conclusions Decreased phosphorylation of PLM reduces Na/K pump activity and exacerbates Na overload, contractile dysfunction, and adverse remodelling following aortic constriction in mice. This suggests a novel therapeutic target for the treatment of heart failure.

    Original languageEnglish
    Pages (from-to)72-82
    Number of pages11
    JournalCardiovascular Research
    Volume104
    Issue number1
    DOIs
    Publication statusPublished - 1 Oct 2014

    Fingerprint Dive into the research topics of 'Cardiac hypertrophy in mice expressing unphosphorylatable phospholemman'. Together they form a unique fingerprint.

  • Projects

    Profiles

    No photo of Will Fuller

    Cite this

    Boguslavskyi, A., Pavlovic, D., Aughton, K., Clark, J. E., Howie, J., Fuller, W., & Shattock, M. J. (2014). Cardiac hypertrophy in mice expressing unphosphorylatable phospholemman. Cardiovascular Research, 104(1), 72-82. https://doi.org/10.1093/cvr/cvu182